

# COMPASS Pathways

COMPASS Pathways is a mental health care company. We are dedicated to accelerating patient access to evidence-based innovation in mental health.

Our work is grounded by personal experiences with mental health suffering and the global burden of depression. We are currently developing psilocybin therapy for treatment-resistant depression.



“ We have experienced the frustration of trying to find effective mental health care for a family member. Along the way, we met many people who had similar feelings of helplessness and disempowerment - we created COMPASS so others wouldn't have to walk the same path. We have to improve patient care and deliver better outcomes. ”

- Ekaterina Malievskaia, Chief Innovation Officer and Co-founder

“ How we operate as a business is as important to us as the science we pursue. We want to improve every patient's experience in mental health care and provide lasting solutions. ”

- George Goldsmith, CEO and Co-founder



We bring together experts from different disciplines to help make a positive difference to people suffering with mental health challenges

## Treatment-resistant depression (TRD) is an urgent, unmet medical need<sup>1</sup>


Described as depression that has **not responded** to at least two different anti-depressants



Depression is the leading cause of **disability** worldwide

**322 million** patients suffer with depression;  
**100 million** of these have TRD

### £300b annual cost of depression



Direct: **£125b**  
Prescription: **£40b**  
Indirect: **£135b**

## About psilocybin therapy

Psilocybin is a psychoactive substance and an active ingredient in so-called 'magic mushrooms'. In our psilocybin therapy protocol, patients are given a dose of our synthesised psilocybin with psychological support from a therapist. This is preceded by, and followed up with, preparation and integration sessions.



COMPASSION<sup>™</sup>  
Navigating Mental Health Pathways

## Psilocybin therapy could improve outcomes for patients with TRD

- In early studies, psilocybin therapy provided rapid reductions in depression symptoms - effects lasted for up to six months after treatment<sup>2</sup>
- Our development programme of psilocybin therapy for treatment-resistant depression received FDA Breakthrough Therapy designation in October 2018

### Our clinical trials

We are committed to open science and rigorous data generation. This is the best way to get innovation to all patients who might benefit from it, safely and quickly.

Healthy volunteers study (phase I, completed 2019)	TRD study (phase IIb, expected completion 2020)
Largest controlled psilocybin study - 89 participants	World's largest psilocybin study - 216 participants
COMP360 (psilocybin) well tolerated, no serious adverse events	18 sites in Europe, US, Canada
No negative effects on cognitive and emotional functioning	Dose-ranging study
Feasibility of simultaneous 1:1 administration	For more information please visit: <a href="https://compasspathways.com/trial">https://compasspathways.com/trial</a>

### Access to innovation

We will ensure our therapies are widely accessible and affordable, helping patients and their families, and creating greater value for healthcare systems and wider society. Our vision is a world of mental wellbeing.

### Patient experience

“Over 70% of patients in early studies rank psilocybin therapy among the top five most meaningful experiences of their lives.”

(Griffiths *et al*, 2016)

“I had a clear mind, it lifted the fog of depression ... The way I felt after, I have not felt with any medicine or therapy or combination.”

(Patient from Imperial College London psilocybin study conducted by Carhart-Harris *et al*, 2016)

### Our values



Compassion



Innovation



Trust



Collaboration

<sup>1</sup>Statistics from World Health Organization

<sup>2</sup>Ross *et al*, 2016; Griffiths *et al*, 2016; Carhart-Harris *et al*, 2016